From fe8ebb5d5cb8269dc9f1e02cdb3f5d64a8d3b514 Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Mon, 19 Feb 2024 16:09:36 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web.md | 4 ++++ 1 file changed, 4 insertions(+) diff --git a/pages/STOP2030___Web.md b/pages/STOP2030___Web.md index 52b0249d..ab8271fe 100644 --- a/pages/STOP2030___Web.md +++ b/pages/STOP2030___Web.md @@ -35,6 +35,10 @@ - Qualification at EMA for art. 58 - Safety of IVM up to 600μg/kg alone and in coformulation with albendazole - Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa + - No stopping rules were reached + - Safety was adequate + - Palatability results confirm adecuacy of size, taste and smell + - Superior efficacy against T. trichiura confirm - ## Otros facts - FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016) - Investigadores principales de cada uno de los partners